UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-39102 TFF PHARMACEUTICALS, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

| --- | --- | --- | --- | --- | --- | |---------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Advanced Technology | | | | | | | for Better Drug Delivery Options | | | | | | | Corporate Presentation – March 2020 | | | | | | SAFE HARBOR STATEMENT 2 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This document contains forward-looking statements concerning TFF Pharmaceuticals, Inc. ("TFF", the "Com ...

| --- | --- | --- | --- | --- | --- | |---------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Advanced Technology | | | | | | | for Better Drug Delivery Options | | | | | | | Corporate Presentation – March 2020 | | | | | | SAFE HARBOR STATEMENT 2 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This document contains forward-looking statements concerning TFF Pharmaceuticals, Inc. ("TFF", the "Com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39102 TFF Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | 82-4344737 | | --- | --- | | (State or Other Juri ...

| --- | --- | --- | --- | --- | |--------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Advanced Technology for Better Drug Delivery Options | | | | | | Corporate Presentation 2019 | | | | | SAFE HARBOR STATEMENT 2 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This document contains forward-looking statements concerning TFF Pharmaceuticals, Inc. ("TFF", the "Company," "we," "us," and "our"). The words "belie ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-39102 TFF PHARMACEUTICALS, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...